Bristol-Myers K.K.
Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
December 21, 2010

Starting co-promotion of the anti-cancer agent
“SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib)
in Japan

Tokyo, Japan -- Bristol-Myers K.K. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Emmanuel Blin) and Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Taro Iwamoto) will start co-promotion activities on the sales of the anti-cancer agent "SPRYCEL Tablet 20mg and SPRYCEL Tablet 50mg" (dasatinib) in Japan on January 1st, 2011.